- Home
- ORGO vs REPL Comparison
ORGO vs REPL Comparison
Compare ORGO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- REPL
- Stock Information
- Founded
- ORGO 1985
- REPL 2015
- Country
- ORGO United States
- REPL United States
- Employees
- ORGO N/A
- REPL N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- REPL Health Care
- Exchange
- ORGO Nasdaq
- REPL Nasdaq
- Market Cap
- ORGO 620.3M
- REPL 547.0M
- IPO Year
- ORGO N/A
- REPL 2018
- Fundamental
- Price
- ORGO $4.08
- REPL $4.66
- Analyst Decision
- ORGO Buy
- REPL Hold
- Analyst Count
- ORGO 3
- REPL 9
- Target Price
- ORGO $7.33
- REPL $6.67
- AVG Volume (30 Days)
- ORGO 800.7K
- REPL 4.7M
- Earning Date
- ORGO 11-06-2025
- REPL 11-11-2025
- Dividend Yield
- ORGO N/A
- REPL N/A
- EPS Growth
- ORGO N/A
- REPL N/A
- EPS
- ORGO N/A
- REPL N/A
- Revenue
- ORGO $429,531,000.00
- REPL N/A
- Revenue This Year
- ORGO $2.51
- REPL N/A
- Revenue Next Year
- ORGO $25.45
- REPL N/A
- P/E Ratio
- ORGO N/A
- REPL N/A
- Revenue Growth
- ORGO N/A
- REPL N/A
- 52 Week Low
- ORGO $2.61
- REPL $2.68
- 52 Week High
- ORGO $6.71
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ORGO 37.32
- REPL 46.86
- Support Level
- ORGO $4.12
- REPL $4.57
- Resistance Level
- ORGO $4.40
- REPL $4.46
- Average True Range (ATR)
- ORGO 0.24
- REPL 0.41
- MACD
- ORGO -0.06
- REPL 0.11
- Stochastic Oscillator
- ORGO 11.96
- REPL 88.99
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.